%0 Journal Article
%T Fanconi syndrome due to tenofovir disoproxil fumarate reversed by
switching to tenofovir alafenamide fumarate in an HIV-infected
patient
%A Deborah J. Marriott
%A Jeffrey Masters
%A Nomvuyo Z. Mothobi
%J Archive of "Therapeutic Advances in Infectious Disease".
%D 2018
%R 10.1177/2049936118785497
%X A case of tenofovir-induced Fanconi syndrome in a patient receiving antiretroviral therapy for HIV infection, with resolution of the related electrolyte abnormalities upon switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate, is reported. Tenofovir alafenamide fumarate, a novel prodrug of tenofovir containing significantly lower doses of tenofovir than tenofovir disoproxil fumarate, has been associated with a favourable renal profile compared to tenofovir disoproxil fumarate. Generally, the rare complication of tenofovir disoproxil fumarate¨Cinduced Fanconi syndrome is managed by cessation of tenofovir. There are limited reports of the impact of a switch strategy from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate, which may be necessary in patients unable to discontinue tenofovir
%K Fanconi syndrome
%K HIV
%K tenofovir
%K tenofovir alafenamide fumarate
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136117/